What is Cannabinoid Hyperemesis Syndrome (CHS)?
This week, we welcome back Dr. Ethan Russo, physician, researcher, and leading expert in the field of Medicinal Cannabis.
In this episode, Dr Russo shares the latest research and findings of the largest study on CHS to date - in which his team identified 6 potential genetic targets to assist in the diagnosis and treatment of the condition.
→ View full show notes, summary, and access resources here:
https://www.canverse.global/shownotes/e120
About Dr. Ethan Russo
Ethan Russo, MD, is a board-certified neurologist, psychopharmacology researcher, and Founder/CEO of CReDO Science https://credo-science.com
Previously he was Director of Research and Development for the International Cannabis and Cannabinoids Institute, 2017-19, Medical Director of PHYTECS, 2015-2017, and from 2003-2014, Senior Medical Advisor, medical monitor/study physician to GW Pharmaceuticals for numerous Phase I-III clinical trials of Sativex® and Epidiolex®.
He was a clinical neurologist in Missoula, Montana for 20 years. He has held faculty appointments in Pharmaceutical Sciences at the University of Montana, and in Medicine at the University of Washington. He is author/editor of seven books and has published more than 50 peer-reviewed articles.
Resources
Join Dr. Russo on LinkedIn: https://www.linkedin.com/in/ethan-russo-md-468b19a/
View Dr. Russo’s clinical research papers: https://www.researchgate.net/profile/Ethan_Russo
CReDO Science Website: https://credo-science.com/
Cannabinoid Hyperemesis Syndrome Survey and Genomic Investigation Paper: https://pubmed.ncbi.nlm.nih.gov/34227878/